TSE:AEZS Aeterna Zentaris (AEZS) Stock Price, News & Analysis → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free AEZS Stock Alerts C$2.66 0.00 (0.00%) (As of 04/23/2024 ET) Add Compare Share Share Today's RangeC$2.66▼C$2.6650-Day RangeC$2.29▼C$2.9152-Week RangeC$1.91▼C$4.48VolumeN/AAverage Volume1,894 shsMarket CapitalizationC$12.93 millionP/E RatioN/ADividend Yield2.79%Price TargetN/A Stock AnalysisStock AnalysisChartCompetitorsHeadlinesStock AnalysisChartCompetitorsHeadlines Get Aeterna Zentaris alerts: Email Address Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… About Aeterna Zentaris Stock (TSE:AEZS)Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications; and AEZS-150, a delayed clearance parathyroid hormonefusion polypeptide that is in preclinical trail for the treatment of hypoparathyroidism in adults. Aeterna Zentaris Inc. has a license agreement with University of Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine; development, manufacture, and commercialization of the treatment for neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. It also has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin in the Republic of Korea; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria EOOD for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults in Turkey and some non-European Union Balkan countries; as well as The University of Sheffield, the United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.Read More AEZS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AEZS Stock News HeadlinesMarch 31, 2024 | theglobeandmail.comAEterna Zentaris: Top 25 Undervalued Toronto Stock Exchange Stocks (AEZS)March 28, 2024 | markets.businessinsider.comCourt Approves Ceapro-Aeterna Merger - Quick FactsApril 25, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.March 28, 2024 | finance.yahoo.comCeapro Receives Final Court Approval for Merger with Aeterna ZentarisFebruary 21, 2024 | benzinga.comAEterna Zentaris Stock (NASDAQ:AEZS) Dividends: History, Yield and DatesFebruary 15, 2024 | msn.comAeterna Zentaris files to sell 2.53M warrantsFebruary 15, 2024 | finance.yahoo.comAeterna Zentaris Issues Letter to Shareholders and Management Proxy Circular Ahead of Special Meeting of Shareholders to Approve Merger of Equals with CeaproJanuary 22, 2024 | theglobeandmail.comClosing Bell: Aeterna Zentaris Inc flat on Monday (AEZS)April 25, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.December 14, 2023 | tmcnet.comAEZS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Aeterna Zentaris Inc. Is Fair to ShareholdersDecember 14, 2023 | marketwatch.comAeterna Zentaris, Ceapro to CombineDecember 14, 2023 | ca.finance.yahoo.comCanadian Investment Regulatory Organization Trade Resumption - AEZSDecember 14, 2023 | markets.businessinsider.comAeterna Zentaris Enters Into Merger Agreement With CeaproDecember 14, 2023 | msn.comAeterna Zentaris and Ceapro to merge in all-stock dealOctober 20, 2023 | theglobeandmail.comAEterna Zentaris: Top 10 Undervalued Growth Stocks on TSX (AEZS)August 9, 2023 | finanznachrichten.deAeterna Zentaris Inc: Aeterna Zentaris Reports Second Quarter 2023 Financial ResultsAugust 9, 2023 | finance.yahoo.comAeterna Zentaris Reports Second Quarter 2023 Financial ResultsJuly 14, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Aeterna Zentaris (AEZS) and Alnylam Pharma (ALNY)July 5, 2023 | finance.yahoo.comAeterna Zentaris to Participate in the Virtual Investor Summer Spotlight SeriesJune 14, 2023 | finance.yahoo.comAeterna Zentaris Announces Results of Virtual 2023 Meeting of ShareholdersMay 25, 2023 | theglobeandmail.comClosing Bell: Aeterna Zentaris Inc down on Thursday (AEZS)May 24, 2023 | theglobeandmail.comClosing Bell: Aeterna Zentaris Inc up on Tuesday (AEZS)May 5, 2023 | theglobeandmail.comClosing Bell: Aeterna Zentaris Inc up on Friday (AEZS)April 21, 2023 | thestreet.comSpeculative Money Propels Biotechs La Jolla Pharma, Aeterna ZentarisApril 10, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Timber Pharmaceuticals (TMBR), Aeterna Zentaris (AEZS) and Cabaletta Bio (CABA)March 28, 2023 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Aeterna Zentaris (AEZS), Delcath Systems (DCTH) and GlaxoSmithKline (GSK)March 23, 2023 | finanznachrichten.deAeterna Zentaris Inc: Aeterna Zentaris Reports Fourth Quarter and Full Year 2022 Financial ResultsSee More Headlines Receive AEZS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aeterna Zentaris and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/24/2024Next Earnings (Estimated)5/07/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolTSE:AEZS CUSIPN/A CIKN/A Webwww.aezsinc.com Phone18439003223FaxN/AEmployees11Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)C($4.63) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeC$-16,550,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-61.34% Return on Assets-24.19% Debt Debt-to-Equity Ratio1.53 Current Ratio8.01 Quick Ratio9.37 Sales & Book Value Annual SalesC$4.50 million Price / Sales2.87 Cash FlowC$5.80 per share Price / Cash Flow0.46 Book ValueC$3.75 per share Price / Book0.71Miscellaneous Outstanding Shares4,860,000Free FloatN/AMarket CapC$12.93 million OptionableNot Optionable Beta2.07 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesDr. Klaus Paulini Ph.D.President, CEO & Executive DirectorMr. Giuliano La FrattaSenior VP of Finance & CFODr. Michael Teifel Ph.D.Senior VP of Non-Clinical Development & Chief Scientific OfficerDr. Nicola Ammer M.D.Chief Medical Officer & Senior VP of Clinical DevelopmentDr. Matthias GerlachSenior Vice President Manufacturing & Supply ChainKey CompetitorsIMVTSE:IMVAntibe TherapeuticsTSE:ATENeptune Wellness SolutionsTSE:NEPTResverlogixTSE:RVXSirona BiochemCVE:SBMView All Competitors AEZS Stock Analysis - Frequently Asked Questions How have AEZS shares performed in 2024? Aeterna Zentaris' stock was trading at C$2.57 at the start of the year. Since then, AEZS shares have increased by 3.5% and is now trading at C$2.66. View the best growth stocks for 2024 here. When is Aeterna Zentaris' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024. View our AEZS earnings forecast. How do I buy shares of Aeterna Zentaris? Shares of AEZS stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. This page (TSE:AEZS) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyPrepare for a recession unlike any otherAmerican Hartford Gold GroupRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldThe #1 Crypto for 2024InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aeterna Zentaris Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
